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Stem cell library screen identified
ruxolitinib as regulator of osteoblastic
differentiation of human skeletal stem cells
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Muhammad Atteya1,4, Abdulaziz Siyal1, Musaad Alfayez1, Abdullah Aldahmash1,5, Moustapha Kassem1,2,6
and Nehad M. Alajez1,7*
Abstract
Background: Better understanding of the signaling pathways that regulate human bone marrow stromal stem cell
(hBMSC) differentiation into bone-forming osteoblasts is crucial for their clinical use in regenerative medicine.
Chemical biology approaches using small molecules targeting specific signaling pathways are increasingly
employed to manipulate stem cell differentiation fate.
Methods: We employed alkaline phosphatase activity and staining assays to assess osteoblast differentiation and
Alizarin R staining to assess mineralized matrix formation of cultured hBMSCs. Changes in gene expression were
assessed using an Agilent microarray platform, and data normalization and bioinformatics were performed using
GeneSpring software. For in vivo ectopic bone formation experiments, hMSCs were mixed with hydroxyapatite–
tricalcium phosphate granules and implanted subcutaneously into the dorsal surface of 8-week-old female nude
mice. Hematoxylin and eosin staining and Sirius Red staining were used to detect bone formation in vivo.
Results: We identified several compounds which inhibited osteoblastic differentiation of hMSCs. In particular, we
identified ruxolitinib (INCB018424) (3 μM), an inhibitor of JAK-STAT signaling that inhibited osteoblastic
differentiation and matrix mineralization of hMSCs in vitro and reduced ectopic bone formation in vivo. Global
gene expression profiling of ruxolitinib-treated cells identified 847 upregulated and 822 downregulated mRNA
transcripts, compared to vehicle-treated control cells. Bioinformatic analysis revealed differential regulation of
multiple genetic pathways, including TGFβ and insulin signaling, endochondral ossification, and focal adhesion.
Conclusions: We identified ruxolitinib as an important regulator of osteoblast differentiation of hMSCs. It is
plausible that inhibition of osteoblast differentiation by ruxolitinib may represent a novel therapeutic strategy for
the treatment of pathological conditions caused by accelerated osteoblast differentiation and mineralization.
Background
Bone marrow stromal (also known as mesenchymal or
skeletal) stem cells (BMSCs) exist within the bone marrow
stromal and are capable for differentiation into
mesoderm-type cells including bone-forming osteoblasts
[1]. A number of signaling pathways have been implicated
in regulating differentiation of human BMSCs (hBMSCs)
into osteoblasts that include TGF-B [2], Wnt [3], and
several intracellular kinases [4]. However, several other
signaling pathways have been reported to regulate differ-
ent aspects of stem cell biology in a number of stem cell
systems [5] but their role in regulating hBMSC differenti-
ation into osteoblastic cells are not well studied.
Chemical biology approaches using small molecules
targeting specific intracellular or signaling factors are
very important tools for studying stem cell differenti-
ation and in vitro manipulation of stem cells (add ref ).
In addition, small molecules that induce stem cell differ-
entiation are being employed as an alternative approach
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to classical stem cell differentiation protocols that re-
quire complex mixture of growth factors and cytokines,
because of their scalable production, stability, ease of
use, and low cost [6–8].
We have previously employed small molecule libraries to
dissection mechanisms underlying differentiation potential
of hBMSCs into osteoblasts [9] [4] and adipocytes [8].
Herein, we conducted an unbiased small molecule
stem cell signaling library screen that covers several sig-
naling pathways and identified ruxolitinib as an import-
ant regulator of osteoblast differentiation of hBMSCs.
Materials and methods
Stem cell signaling compound library
A stem cell signaling compound library, purchased from
Selleckchem Inc. (Houston, TX, http://www.selleck
chem.com) and consisted of 73 biologically active small
molecular inhibitors, was employed in the presented
study. An initial screen was conducted at a concentra-
tion of 3 μM.
Cell culture
We employed a telomerized hMSC line (hMSC-TERT)
as a model for hBMSCs. The hMSC-TERT line was gen-
erated through an overexpression of the human telomer-
ase reverse transcriptase gene (hTERT). hMSC-TERT
exhibits the typical features of primary hMSCs including
indefinite self-renewal and multipotency, in addition to
the expression of all known markers of primary hMSCs
[10–12]. The cells were maintained in DMEM, a basal
medium supplemented with 4500 mg/L D-glucose,
4 mM L-glutamine, and 110 mg/L 10% sodium pyruvate,
in addition to 10% fetal bovine serum (FBS), 1% penicil-
lin–streptomycin, and 1% nonessential amino acids. All
reagents were purchased from Thermo Fisher Scientific,
Waltham, MA (http://www.thermofisher.com). Cells
were incubated in 5% CO2 incubators at 37 °C and 95%
humidity.
Osteoblast differentiation
The cells were cultured to 80–90% confluence and were
incubated in osteoblast induction medium (DMEM con-
taining 10% FBS, 1% penicillin–streptomycin, 50 μg/ml
L-ascorbic acid (Wako Chemicals GmbH, Neuss,
Germany, http://www.wako-chemicals. de/), 10 mM
b-glycerophosphate (Sigma-Aldrich), 10 nM calcitriol
(1a,25-dihydroxyvitamin D3; Sigma-Aldrich), and 10 nM
dexamethasone (Sigma-Aldrich)). Each small molecule
inhibitor was added at a concentration of 3 μM, in
the osteoblast induction medium. The cells were ex-
posed to the inhibitors throughout the differentiation
period. Control cells were treated with osteoblast in-
duction medium containing dimethyl sulfoxide
(DMSO) as vehicle.
Cell viability assay
Cell viability assay was performed using alamarBlue
assay according to the manufacturer’s recommendations
(Thermo Fisher Scientific). In brief, cells were cultured
in 96-well plates in 200 μl of the medium for 10 days,
then 20 μl of alamarBlue substrate was added, and plates
were incubated in the dark at 37 °C for 1 h. Readings
were taken using fluorescent mode (Ex 530 nm/Em
590 nm) using a BioTek Synergy II microplate reader
(BioTek Inc., Winooski, VT, USA).
Alkaline phosphatase activity quantification
To quantify alkaline phosphatase (ALP) activity, we
employed the BioVision ALP activity colorimetric assay
kit (BioVision, Inc., Milpitas, CA, http:// www.biovision.
com/) with some modifications. The cells were cultured
in 96-well plates. On day 10, the cells were rinsed once
with phosphate-buffered saline (PBS) and fixed using
3.7% formaldehyde in 90% ethanol for 30 s at room
temperature. Fixative was removed, and 50 μl of
p-nitrophenyl phosphate solution was added to each well
and incubated for 30–60 min. Optical densities were
then measured at 405 nm using a SpectraMax/M5 fluor-
escence spectrophotometer plate reader. ALP enzymatic
activity was normalized to cell number.
In vivo ectopic bone formation assay
All animal experimental procedures were approved by
the Animal Care Committees of King Saud University.
Cells were harvested via trypsinization, washed in PBS,
and resuspended in culture medium with or without
ruxolitinib. Approximately 5 × 105 cells were mixed with
40 mg of hydroxyapatite–tricalcium phosphate granules
per each implant (HA/TCP, Zimmer Scandinavia,
Albertslund, Denmark) and implanted subcutaneously
into the dorsal surface of 8-week-old female nude mice,
as previously described [13]. After 28 days, the implants
were recovered, fixed in 4% paraformaldehyde, decalci-
fied using formic acid solution (0.4 M formic acid and
0.5 M sodium formate), and embedded in paraffin.
Tissue blocks were sectioned at 4 μm. Sections of
paraffin-embedded implants were stained with
hematoxylin and eosin and Sirius Red to identify areas
of the formed bone.
Alkaline phosphatase staining
Cells were stained on day 10 of osteoblast differenti-
ation. Cells cultured in 12-well plates were washed in
PBS and fixed in 10 mM acetone/citrate buffer at pH 4.2
for 5 min at room temperature. The fixative was
removed, and the Naphthol/Fast Red stain [0.2 mg/mL
Naphthol AS-TR phosphate substrate (Sigma)]
[0.417 mg/mL of Fast Red (Sigma)] was added for 1 h at
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room temperature. The cells were then rinsed with
water and imaged under the microscope.
Alizarin Red S staining for mineralized matrix formation
Cells cultured in 12-well plates were stained on day 21
of osteoblast differentiation. The cells were washed twice
with PBS and then fixed with 4% paraformaldehyde for
15 min at room temperature. Fixative was then removed,
and the cells were washed with distilled water and
stained with 2% Alizarin Red S Staining Kit (ScienceCell,
Research Laboratories, Cat. No. 0223) for 20–30 min at
room temperature. Subsequently, the dye was washed off
with water and cells were imaged under the microscope.
RNA extraction and cDNA synthesis
Total RNA was isolated from cell pellets after 10 and
21 days of osteoblast differentiation using the total RNA
Purification Kit (Norgen Biotek Corp., Thorold, ON,
Canada, https://norgenbiotek.com/) according to the
manufacturer’s protocol. The concentrations of total
RNA were measured using NanoDrop 2000 (Thermo
Fisher Scientific). cDNA was synthesized using 500 ng of
total RNA and the Thermo Fisher Scientific High
Capacity cDNA Transcription Kit according to the
manufacturer’s protocol.
qRT-PCR
Expression levels of the mRNAs were validated using SYBR
Green-based quantitative reverse transcriptase-polymerase
chain reaction (qRT-PCR) with an Applied Biosystems ViiA™
7 Real-Time PCR System (Thermo Fisher Scientific).
Primers used in current study are listed in Table 1.
The 2ΔCT value method was used to calculate rela-
tive expression, and analysis was performed as previ-
ously described [14].
Gene expression profiling by microarray
One hundred fifty nanograms of total RNA was labeled
using low input Quick Amp Labeling Kit (Agilent Tech-
nologies, Santa Clara, CA, http://www.agilent.com) and
then hybridized to the Agilent Human SurePrint G3
Human GE 8 × 60 k microarray chip. All microarray
experiments were performed at the Microarray Core
Facility (Stem Cell Unit, Department of Anatomy, King
Saud University College of Medicine, Riyadh, Saudi
Arabia). The extracted data were normalized and
analyzed using GeneSpring 13.0 software (Agilent Tech-
nologies). Pathway analyses were performed using the
single experiment pathway analysis feature in Gene-
Spring 13.0 as described before [15]. Twofold cutoff and
P (corr) < 0.05 (Benjamini–Hochberg multiple testing
corrected) were used to determine significantly changed
transcripts.
Statistical analysis
Statistical analysis and graphing were performed using
Microsoft Excel 2010 and GraphPad Prism 6 software
(GraphPad software, San Diego, CA, USA), respectively.
Results were presented as mean ± SEM from at least two
independent experiments. Unpaired t test was used to
determine statistical significance and P values < 0.05 was
considered statistically significant.
Results
Stem cell signaling library screen identified inhibitors of
osteoblast differentiation of hBMSCs
A stem cell signaling library consisting of 73 chemical
compounds was used for the initial screen for their
effects on osteoblastic differentiation of hBMSCs using
ALP activity quantification as a read-out. All small mole-
cules were tested at a concentration 3 μM. As shown in
Fig. 1, the majority of small molecules reduced ALP ac-
tivity of hBMSCs. Based on this initial screen, we chose
11 compounds (ruxolitinib (INCB018424), LY411575,
BMS-833923, sotrastaurin, SB525334, LGK-974,
ICG-001, BIO, TWS119, fasudil (HA-1077) HCl, and
baricitinib (LY3009104, INCB028050)) for follow-up
studies. The name of small molecule and their molecular
targets are listed in Table 2. As shown in Fig. 2, several
of the tested molecules inhibited osteoblastic differenti-
ation of hBMSCs as evidenced by reduced ALP cytochem-
ical staining at day 10 post-osteoblast differentiation
Table 1 Real-time PCR primer sequences
Gene name Forward primer Reverse primer
ACTB 5′AGCCATGTACGTTGCTA 5′AGTCCGCCTAGAAGCA
ALP 5′GGA ACT CCT GAC CCT TGA CC3′ 5′TCC TGT TCA GCT CGT ACT GC3′
RUNX2 5′GTA GAT GGA CCT CGG GAA CC3′ 5′GAG GCG GTC AGA GAA CAA AC3′
COMP 5′CCGACACCGCCTGCGTTCTT3′ 5′AGCGCCGCGTTGGTTTCCTG3′
THBS2 5′TTGGCAAACCAGGAGCTCAG3′ 5′GGTCTTGCGGTTGATGTTGC3′
TNF 5′ACT TTG GAG TGA TCG GCC3′ 5′GCT TGA GGG TTT GCT ACA AC3′
LIF 5′GCCACCCATGTCACAACAAC 5′CCCCCTGGGCTGTGTAATAG
SOCS3 5′TTCGGGACCAGCCCCC3′ 5′AAACTTGCTGTGGGTGACCA3′
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induction (Fig. 2a) and this was concordant with the
reduced ALP activity (Fig. 2b). These molecules did not
exert significant effects on hBMSC viability (Fig. 2c).
Among these small molecules, we chose ruxolitinib
(INCB018424) for more detailed studies as it yielded
the most consistent and potent effect on osteoblast
differentiation and its effect on osteoblast differentiation
of hBMSCs has not been studied before.
Ruxolitinib inhibits mineralized matrix formation
To assess the effects of ruxolitinib on mineralized matrix
formation, hBMSCs were treated with ruxolitinib (3 μM)
Fig. 1 Functional screen of stem cell signaling small molecule library for their effects on osteoblast differentiation of human bone marrow stromal
stem cells (hBMSCs). hBMSCs were induced into osteoblasts for 10 days in the presence of the indicated small molecule inhibitors (3.0 μM) or DMSO
vehicle control. Data are presented as mean alkaline phosphatase (ALP) activity ± SEM, n≥ 10 from three independent experiments. Small molecules
are grouped according to their targeted signaling pathway. DMSO dimethyl sulfoxide. *P < 0.05; **P < 0.05; ***P < 0.0005
Table 2 Characteristics of the selected 11 compounds of stem cell signaling library
Name of compound Target Pathway
LY411575 Gamma-secretase Proteases
Sotrastaurin PKC TGF-beta/Smad
SB525334 TGF-beta/Smad TGF-beta/Smad
Ruxolitinib (INCB018424) JAK1/JAK2 JAK/STAT
LGK-974 Wnt/beta-catenin Stem cells and Wnt
ICG-001 Wnt/beta-catenin Stem cells and Wnt
BIO GSK-3 PI3K/Akt/mTOR
TWS119 GSK-3 PI3K/Akt/mTOR
Fasudil (HA-1077) HCl ROCK Cell cycle
Baricitinib (LY3009104, INCB028050) JAK Epigenetics
BMS-833923 Hedgehog/smoothened GPCR and G protein
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and induced into osteoblast for 21 days. Alizarin Red
staining demonstrated significant reduction in mineral-
ized matrix formation in ruxolitinib-treated hBMSCs
compared to vehicle-treated controls (Fig. 3a). Similarly,
ruxolitinib reduced the expression of ALP and RUNX2
osteoblast gene markers measured on day 10 (b) or day
21 (c) post-osteoblast induction.
Ruxolitinib affects multiple signaling pathways during
osteoblast differentiation of hBMSCs
To understand the molecular mechanism by which ruxoli-
tinib inhibits osteoblast differentiation of hBMSCs, we
performed global gene expression profiling and pathway
analysis comparing ruxolitinib-treated and DMSO-treated
control cells, during osteoblast differentiation. Figure 4a
shows the hierarchical clustering based on the
differentially expressed genes and demonstrates clear sep-
aration of ruxolitinib-treated and DMSO (vehicle)-treated
control cells. We identified 847 upregulated and 822
downregulated genes (fold change ≥ 2.0; P (corr) < 0.05)
(Additional file 1). Pathway analysis of the downregulated
genes revealed strong enrichment for several cellular pro-
cesses involved in osteoblast differentiation (e.g., TGFβ
signaling, insulin signaling, endochondral ossification, and
focal adhesion). A number of significantly enriched path-
ways in ruxolitinib-treated cells are illustrated as a pie
chart (Fig. 4b), wherein the size of the slice corresponds to
fold enrichment. Among the identified pathways, TGFβ
signaling, insulin signaling, and focal adhesion signaling
were prominent. These genetic pathways are known for
their role in regulating osteoblast differentiation of
hBMSCs. A number of genes from the enriched pathways
Fig. 2 The effect of a selected panel of small molecules targeting multiple signaling pathways on osteoblast differentiation of hBMSCs. a
Representative alkaline phosphatase (ALP) staining of hBMSCs on day 10 following treatment with the indicated compounds (concentration
3.0 μM). Images were taken at × 10 magnification using a Zeiss inverted microscope. b Quantification of ALP activity in hBMSCs following
treatment with the indicated compounds (concentration 3 μM) versus vehicle-treated control cells at day 10. Data are presented as mean
percentage ALP activity ± SEM, n > 16. **P < 0.05; ***P < 0.0005. c Cell viability assay using alamarBlue showing the relative cell viability in hBMSCs
following treatment with the indicated compounds (3 μM) versus vehicle-treated control cells on day 10 post-osteoblast differentiation.
Abbreviations: ALP alkaline phosphatase, DMSO dimethyl sulfoxide
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(TNF, LIF, SOCS3, COMP, and THBS2) were selected and
validated using qRT-PCR, which collectively corroborated
the microarray data (Fig. 4c).
Effects of ruxolitinib on in vivo ectopic bone formation
To determine the regulatory role of ruxolitinib on in
vivo bone formation, we implanted hBMSCs loaded on
hydroxyapatite–tricalcium phosphate (HA/TCP) gran-
ules in the presence or absence of ruxolitinib into nude
mice for 4 weeks. Histological analysis of the implants
showed significant decrease in the formed ectopic bone
in ruxolitinib-treated hBMSCs compared to control
hBMSCs (Fig. 5a, b).
Discussion
Small molecules, targeting specific signaling pathways,
have recently emerged as a key tool to manipulate stem
cell fate and differentiation potential in both mechanistic
studies of stem cell biology as well as an approach to
generate cells suitable for clinical use [6]. In the current
study, we employed a well-characterized stem cell signal-
ing library and performed unbiased functional screen on
73 small molecules targeting a number of signaling
pathways relevant for hBMSC biology. These molecules
covered a number of proteases, TGF-beta/Smad, JAK/
STAT, Wnt, PI3K/Akt/mTOR, neuronal signaling, cell
cycle, epigenetics, GPCR and G protein, Hedgehog, and
GSK-3 inhibitors. Our initial screen identified several
small molecule inhibitors, mainly targeting the
JAK-STAT pathway, as potent inhibitors of osteoblastic
differentiation of hBMSCs. In particular, ruxolitinib, a
novel JAK-targeting small molecule inhibitor, was fur-
ther studied and validated as a potent inhibitor of osteo-
blast differentiation.
JAK1 and JAK2 modulate the intracellular signaling of
significant cytokines and growth factors for
hematopoiesis and immune function including activation
of signal transducers and activators of transcription
(STAT). STAT3 is a ubiquitously expressed transcription
factor activated by many cytokines and growth factors,
including IL-6 family cytokines [16]. The receptors for
the IL-6 family cytokines comprise of a ligand-binding
subunit and a common signal-transducing subunit,
gp130. Upon binding to their receptors, gp130 becomes
activated leading to the activation of gp130-associated
JAK (JAK1, JAK2, and TYK2) that subsequently lead to
Fig. 3 The effect of ruxolitinib on osteoblastic differentiation of hBMSCs. a hMSCs were induced into osteoblasts for 21 days in the absence (left
panel) or presence (right panel) of ruxolitinib and were stained for mineralized matrix formation using Alizarin Red stain. Images were taken at ×
10 magnification using a Zeiss inverted microscope. Quantitative RT-PCR analysis for gene expression of alkaline phosphatase (ALP) and RUNX2 in
hBMSCs inducted into osteoblasts for 10 days (b) or 21 days (c) in the absence (blue) or presence (red) of ruxolitinib. Cells treated with DMSO
were used as control. Gene expression was normalized to β-actin. Data are presented as mean fold change ± SEM (n = 6) from two independent
experiments. ***P ≤ 0.0005. Abbreviations: ALP alkaline phosphatase, RUNX2 runt-related transcription factor 2, DMSO dimethyl sulfoxide
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tyrosine phosphorylation of STAT3. Activated STAT3
localize to the nucleus and modulate various gene ex-
pression that regulate cell proliferation and differenti-
ation in a cell-specific manner including bone
metabolism [17]. The role of JAK-STAT signaling in
osteoblastic differentiation is starting to unfold. For in-
stance, inactivation and mutations of STAT3 in osteo-
blasts and osteocytes lead to distorted craniofacial and
skeletal features, recurrent fractures, hyperextensible
joints, reduce bone mass, strength, and load-driven bone
formation, suggesting a role for STAT3 in osteoblast
differentiation [18]. JAK-STAT signaling has been
implicated in the maintenance of the stem cell pool in
Drosophila and mammals [19]. Our findings from
current study provide new evidence of potential involve-
ment of JAK-STAT signaling in hBMSC biology.
Although in current study we did not investigate the
downstream targets of ruxolitinib, it is well established
that ruxolitinib is an ATP-competitive JAK1/2 inhibitor
[20–22]. JAK1-deficient mice weighed less than their
heterozygous and wild-type littermates, suggesting an
important role for JAK1 in skeletal development [23].
Mouse embryonic fibroblasts derived from JAK2-deficient
mice exhibited defects in signaling through a number of
cytokine receptors, implying plausible role for JAK2 in
skeletal development [24]. Cells treated with ruxolitinib
exhibited diminished levels of phosphorylated STAT3,
STA4, and STAT5 [25]. Therefore, it is plausible that
ruxolitinib regulated osteoblastic differentiation of
hBMSCs through inhibition of JAK-STAT3 signaling.
Ruxolitinib might additionally inhibit other pathways
known to be regulated by JAK, such as PI3K-AKT or
Fig. 4 Ruxolitinib affects multiple pathways during osteoblastic differentiation of hBMSCs. a Heat map analysis and unsupervised hierarchical
clustering performed on differentially expressed genes during osteoblast differentiation of ruxolitinib-treated compared to DMSO-treated control
hBMSCs. b Pie chart illustrating the distribution of selected enriched pathway categories for the downregulated genes identified in osteoblast
differentiated ruxolitinib-treated hBMSCs compared to DMSO-treated control cells. c Validation of a selected panel of downregulated genes
during osteoblastic differentiation of ruxolitinib-treated hBMSCs compared to DMSO-treated control cells using qRT-PCR. Gene expression was
normalized to β-actin. Data are presented as mean fold change ± SEM (n = 6) from two independent experiments; *P < 0.05; ***P < 0.0005
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ERK-JNK-p38, contributing to inhibition of osteoblastic
differentiation [26, 27].
Global gene expression profiling of hMSC treated with
ruxolitinib revealed multiple differentially regulated sig-
naling pathways including TGFβ, insulin, endochondral
ossification, and focal adhesion signaling, which are
known to play an important role in regulating osteo-
blastic differentiation of hMSCs [28–33]. Those data are
concordant with other published reports implicating
protease-activated receptors [34], TGF-beta [2], Wnt/
β-catenin [35], PI3K/Akt [36], cell cycle [37], and GPCR
[38] signaling during osteogenesis.
Ruxolitinib is currently used in the clinic to treat pa-
tients with myelofibrosis, a clonal myeloproliferative
neoplasm [39]. Ruxolitinib exhibited growth inhibition,
apoptosis induction, and drop in inflammatory cytokine,
mediated by inhibition of phosphorylate STAT via inhib-
ition of JAK [20, 40]. No previous reports have been
published regarding the effects of ruxolitinib on the
osteoblast differentiation of hMSCs. We therefore inves-
tigated the expression of a selected panel of inflamma-
tory cytokine (CXCL2, TNF, IL6, and CXCL1) from the
microarray data during osteogenesis of hMSCs exposed
to ruxolitinib and observed significant downregulation
in the expression of those cytokines. While conceivable
that small molecule inhibitors have specific targets, a
number of studies have indicated deleterious effects of
small molecule inhibitors on the biological function of
mammalian cells [41, 42]. In particular, it was shown
that hBMSCs are prone to cellular senescence under
stress conditions [43]. Although we did not observe a
significant change in cell viability of hBMSCs treated
with ruxolitinib (3.0 μM) in the current study, it is
plausible that inhibition of osteogenesis by ruxolitinib is
in part due to possible effect on cellular senescence.
Enhancing bone formation and bone mass is needed in
many conditions associated with bone loss such as in
post-menopausal osteoporosis and glucocorticoid-induced
osteoporosis, and suppression of osteogenic differentiation
of hBMSCs by ruxolitinib may be relevant to a number of
clinical conditions associated with ectopic bone formation
or calcification including craniosynostosis and heart valve
calcification [44, 45]. The clinical effectiveness of ruxoliti-
nib in these conditions requires further studies.
Conclusion
Our unbiased small molecule screen identified ruxoliti-
nib, a JAK-STAT inhibitor, as potent inhibitor of osteo-
blastic differentiation of hBMSCs. Inhibition of bone
formation by ruxolitinib might represent a novel thera-
peutic strategy for the treatment of pathological condi-
tions caused by accelerated osteoblast differentiation and
mineralization.
Additional file
Additional file 1: List of differentially expressed genes (2.0 FC, p corr < 0.05)
in human bone marrow mesenchymal stem cells (hBMSCs) differentiated into
osteoblasts (day 10) in the presence of Ruxolitinib compared to DMSO.
Differentially expressed genes (2.0 FC, p corr < 0.05) in human bone marrow
mesenchymal stem cells (hBMSCs) differentiated into osteoblasts (day 10) in
the presence of Ruxolitinib compared to DMSO detected using microarray.
(XLSX 365 kb)
Fig. 5 Ruxolitinib inhibits in vivo ectopic bone formation. Ruxolitinib-treated and control hBMSCs were implanted with hydroxyl apatite/tricalcium
phosphate (HA/TCP) subcutaneously into NOD/SCID mice. The histology of in vivo bone formation was examined with H&E (a) and Sirius red (b)
staining. Black arrows indicate the bone formation (× 20), and black line shows the bone formed zone with osteoblast between the HA and
spindle-shaped hMSCs (× 40). Images were taken at × 20 (first row; scale bar = 100 μm) and × 40 (second row; scale bar = 50 μm) magnification
using a light microscope. Abbreviation: H&E hematoxylin and eosin
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ALP: Alkaline phosphatase; ALZR: Alizarin Red; DMEM: Dulbecco’s modified
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tricalcium phosphate; hBMSCs: Human bone marrow stromal stem cell;
hTERT: Human telomerase reverse transcriptase; JAK: Janus kinase;
PBS: Phosphate-buffered saline; qRT-PCR: Quantitative reverse transcriptase-
polymerase chain reaction
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